Polyamines buffer iron suppress ferroptosis
Analysis based on 7 articles · First reported Aug 14, 2026 · Last updated Sep 02, 2026
This fundamental biological discovery could influence drug development strategies in oncology, potentially leading to combination therapies targeting polyamine and GPX4 pathways. It may also spur research into iron-related neurodegeneration, but near-term market impact is limited as the findings are preclinical.
Researchers at the Massachusetts Institute of Technology and Whitehead Institute, led by Ankur Jain, Whitney Henry, and Pushkal Sharma, discovered that polyamines, small molecules abundant in cells, act as storage lockers for iron, keeping it in a non-reactive state and preventing toxic iron overload. The findings, published in the journal Cell on August 14, 2026, solve a decades-old mystery about why cells maintain high polyamine levels. Using a genome-wide genetic screen and a novel fluorescent iron sensor, they showed that reduced polyamine levels increase chemically reactive iron, making cells dependent on the protein GPX4 for survival. This mechanism suppresses ferroptosis, a form of iron-dependent cell death. The discovery has implications for cancer treatment, suggesting that combining polyamine-lowering drugs with GPX4 inhibitors could be more effective. It also offers a possible link between polyamine mutations and iron accumulation in early-onset Parkinson's disease. The research was supported by the United States — National Institutes of Health, Bumpus Foundation, and Al-Falah Charitable Trust.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard